QT Medical announces FDA clearance of PCA 500, a resting 12-lead electrocardiogram (ECG or EKG), for use in pediatric patients. First cleared in 2018 for professional and personal use by adults 18 years and older, PCA 500's new FDA clearance expands its indication for use to all pediatric populations, including: newborns, infants, children and adolescents.

QT Medical, Inc. (QT Medical), a medtech company focusing on electrocardiogram (ECG or EKG) technology, announces today that it raised $12 million in Series B financing. This funding will accelerate QT Medical’s market penetration, global expansion, product pipeline development, and long-term strategic planning.

The facts are grim: One person dies from cardiovascular disease every 37 seconds in the United States. One of the most effective tests for the heart is the twelve-lead electrocardiogram (ECG).

Many fields of medicine are undergoing a transformation due to the COVID-19 pandemic, as patients are kept away from clinics as much as possible.

Las Vegas-- 01/11/2019 -- QT Medical announces the launch of its Personal Cardiac Assistant (PCA 500) at the world’s largest technology showcase, CES. PCA 500 is the only FDA-cleared, hospital quality 12-lead electrocardiogram (ECG) for personal use. QT Medical’s CEO Dr. Ruey-Kang Chang and his team exhibited the PCA 500 at the startup zone in Eureka Park.

We are honored to cordially invite you to visit our booth at Healthcare+ Expo Taiwan 2021

QT Medical strives to make hospital grade 12-lead electrocardiograms (ECG) accessible to everyone everywhere.

QT ECG is selected to be among 4 Finalists in the Life Science Research Tools and Medical Device Category